The effect of thriphala, a herbal Ayurveda formulation, on serum lipids, in patients on a maintenance dose of atorvastatin for hyperlipidaemia: a randomized controlled trial

Abstract

Introduction Thriphala, a herbal medicinal formulation, is a bedrock of Ayurveda therapeutics with many postulated benefits.

Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review

“…The studies were published between 1990 and 2019. Most of the studies are relatively small-sized trials but 2 studies 16 , 32 enrolled more than 100 patients. Eight studies enrolled middle aged participants and 2 studies contained young participants as low as teens.…”

“…Three studies 16 , 17 , 28 were performed on dyslipidemia patients and 6 studies 4 , 22 , 27 , 30 – 32 were performed on obese patients. Two studies were performed on prediabetes 10 and diabetes type II patients.…”

“…While 1 study in Thailand 17 showed triphala decreased LDL-C (10.89%, p < 0.05) and TG (14.39%, p < 0.05) when compared to the baseline level. Moreover, Ekanayaka study 16 undertook effect of triphala adjunct statin therapy compared placebo in hypercholesterolemia. The results found triphala treatment did not show additional lowering effect on LDL-C, TG and HDL levels in dyslipidemia patients with Atorvastatin 10 mg daily.…”

“…Triphala-treated group reduced FBS and HbA1c levels significantly compared to baseline level, however, there were no significant difference in both FBS and HbA1c levels between triphala-treated and placebo groups. 4 , 16 , 19 , 29 One study 22 investigated effects of triphala formula on blood glucose in obese patients. This study found triphala formula 1,800 mg/day was not significantly decreased HbA1c level compare to placebo group.…”

Effect of an aqueous extract of Terminalia chebula on endothelial dysfunction, systemic inflammation, and lipid profile in type 2 diabetes mellitus: A randomized double‐blind, placebo‐controlled clinical study

“…In a T A B L E 6 Effect of the treatments on the safety parameters randomized double-blind clinical, a polyherbal formulation, containing T. chebula, significantly reduced the serum hsCRP level compared to the baseline value in an obese adolescent population (Shivakumar, Ilango, Dubey, Subhasree, & Agrawal, 2015). However, the administration of Triphala, containing T. chebula, Terminalia bellerica, and P. emblica, failed to exhibit a significant reduction in the serum hsCRP level compared to placebo in hypolipidemic adults receiving atorvastatin (Ekanayaka, Rupasinha, Sooriyarachchi, & Goonaratna, 2017).…”